Deciding when to stop immunotherapy: exploring KEYNOTE-006 data

At the recent Annual Meeting of the American Society of Clinical Oncology (ASCO; 1–5 June 2018, IL, USA) meeting, data was presented highlighting the survival rates for patients who completed the KEYNOTE-006 Phase III study, for pembrolizumab given to unresectable or metastatic melanoma patients. It also gave insight on the follow up of patients who had a response. Of those who did the entire 2-year cycle of treatments, 86% remained without progressive disease 20 months after stopping. In other words, 89 of 109 patients that had either a complete response, partial response, or stable disease didn’t get any worse for...